Polymorphic oxidative metabolism of proguanil in a Nigerian population

被引:16
作者
Bolaji, OO [1 ]
Sadare, IO [1 ]
Babalola, CP [1 ]
Ogunbona, FA [1 ]
机构
[1] Obafemi Awolowo Univ, Fac Pharm, Dept Pharmaceut Chem, Ife, Osun State, Nigeria
关键词
Nigerians; CYP2C19; malaria; proguanil;
D O I
10.1007/s00228-002-0509-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective The genetic polymorphic metabolic oxidation of proguanil was investigated in 126 healthy, unrelated Nigerian subjects as an indication of the phenotypic status of CYP2C19 in Nigerians. Methods: The proguanil oxidation capacity was determined using the 8-h urinary metabolic ratio of the parent drug and its metabolite (cycloguanil) after a single oral dose of 200 mg proguanil. Results: The frequency distribution of the proguanil metabolic ratio ranged from 0.01 to 39.64 with a median of 1.38 in the 126 Nigerians. On the basis of the antimode value of 10 for the proguanil/cycloguanil ratio, the prevalence of poor metabolisers in this Nigerian population was estimated to be 4.8% (6 of 126), which is very similar to that of S-mephenytoin (4.3%) found in a previous study in Nigerians. The data also demonstrated enormous inter-individual differences in the urinary proguanil/cycloguanil ratios with poor metabolisers excreting, on average, only about 8% of the quantity of cycloguanil excreted by extensive metabolisers. Conclusion: The incidence of phenotypically poor metabolisers of proguanil in this Nigerian population is similar to those reported for Caucasian and other African populations but is much lower than those reported for Orientals. The study further supports previous studies that proguanil can be used as an alternative probe to phenotype for CYP2C19 activity.
引用
收藏
页码:543 / 545
页数:3
相关论文
共 22 条
[1]   Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population [J].
Basci, NE ;
Bozkurt, A ;
Kortunay, S ;
Isimer, A ;
Sayal, A ;
Kayaalp, SO .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (06) :771-773
[2]   IN-VITRO PROGUANIL ACTIVATION TO CYCLOGUANIL BY HUMAN LIVER-MICROSOMES IS MEDIATED BY CYP3A ISOFORMS AS WELL AS BY S-MEPHENYTOIN HYDROXYLASE [J].
BIRKETT, DJ ;
REES, D ;
ANDERSSON, T ;
GONZALEZ, FJ ;
MINERS, JO ;
VERONESE, ME .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (05) :413-420
[3]   PROGUANIL METABOLISM IS DETERMINED BY THE MEPHENYTOIN OXIDATION POLYMORPHISM IN VIETNAMESE LIVING IN DENMARK [J].
BROSEN, K ;
SKJELBO, E ;
FLACHS, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (02) :105-108
[4]   OXIDATIVE ACTIVATION OF PROGUANIL AND DAPSONE ACETYLATION IN THAI SOLDIERS [J].
EDSTEIN, MD ;
SHANKS, GD ;
TEJAISAVADHARM, P ;
RIECKMANN, KH ;
WEBSTER, HK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (01) :67-70
[5]   Influence of gender and oral contraceptives on CYP2D6 and CY2ZC19 activity in healthy volunteers [J].
Hägg, S ;
Spigset, O ;
Dahlqvist, R .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (02) :169-173
[6]   THE PHARMACOKINETICS AND ACTIVATION OF PROGUANIL IN MAN - CONSEQUENCES OF VARIABILITY IN DRUG-METABOLISM [J].
HELSBY, NA ;
WARD, SA ;
EDWARDS, G ;
HOWELLS, RE ;
BRECKENRIDGE, AM .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (04) :593-598
[7]   INVITRO METABOLISM OF THE BIGUANIDE ANTIMALARIALS IN HUMAN LIVER-MICROSOMES - EVIDENCE FOR A ROLE OF THE MEPHENYTOIN HYDROXYLASE (P450-MP) ENZYME [J].
HELSBY, NA ;
WARD, SA ;
HOWELLS, RE ;
BRECKENRIDGE, AM .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (02) :287-291
[8]   Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype [J].
Herrlin, K ;
Massele, AY ;
Rimoy, G ;
Alm, C ;
Rais, M ;
Ericsson, Ö ;
Bertilsson, L ;
Gustafsson, LL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (02) :189-198
[9]  
IYUN AO, 1990, BRIT J CLIN PHARMACO, V30, pP312
[10]   Interethnic differences in drug metabolism: Influence of genetic and environmental factors on debrisoquine hydroxylation phenotype [J].
Llerena, A ;
Cobaleda, J ;
Martinez, C ;
Benitez, J .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1996, 21 (02) :129-138